Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

Let’s look specifically at dexamethasone, a common corticosteroid in emergency medicine, and use current research to describe what the drug does and look at select situations in prehospital care ...

Objective: To compare the efficacy and tolerability of dexamethasone-21-palmitate and ... mepivacaine only or a combination of the two drugs there was a 63% and 60%, respectively, reduction ...

Consisting of five separate booklets, the World Drug Report 2022 provides an in-depth analysis of global drug markets and examines the nexus between drugs and the environment within the bigger picture ...

New Delhi: In line with the 'Not of Standard Quality' data provided by states, the apex drug regulatory body, the Central ...

Drug delivery describes the method and approach to delivering drugs or pharmaceuticals and other xenobiotics to their site of action within an organism, with the goal of achieving a therapeutic ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

China NMPA approves Sanofi’s Sarclisa for patients with newly diagnosed multiple myeloma ineligible for transplant: Paris Saturday, February 1, 2025, 12:00 Hrs [IST] The Nationa ...